Sandoz biosimilar Erelzi matches efficacy, safety profile of reference biologic in rheumatoid arthritis
Sandoz, a Novartis division and the global leader in biosimilars, announces results from the EQUIRA study. The phase III comparative...
Adaptive Biotechnologies Announces a Collaboration with Amgen to Advance Clinical Development of the clonoSEQ Assay in Multiple Myeloma
Adaptive Biotechnologies, a leader in combining next-generation sequencing (NGS) and sophisticated bioinformatics to profile T- and B-cell receptors of the...
Dermira and UCB Agree to End Collaboration Agreement for CIMZIA
Dermira, Inc and UCB announced the companies have agreed to end their development and commercialization agreement for CIMZIA (certolizumab pegol)...
Abbott’s Mitraclip Approved As First Transcatheter Mitral Valve Repair Device In Japan
Abbott announced that Japan's Ministry of Health, Labour and Welfare (MHLW) has approved the company's MitraClip device for treatment of...
Otsuka Announces Phase 3 Results for Tolvaptan in Patients with Autosomal Dominant Polycystic Kidney Disease (ADPKD)
Otsuka Pharmaceutical Co., Ltd. (Otsuka) announced detailed results from the Phase 3 REPRISE trial of tolvaptan, which is under investigation...
INC Research/inVentiv Health to Present at Upcoming Jefferies 2017 London Healthcare Conference
INC Research/inVentiv Health (Nasdaq:INCR), the only fully integrated biopharmaceutical solutions organization, today announced that Chief Executive Officer Alistair Macdonald is...
Servier Germany to co-promote Novartis’ blockbuster Entresto®
Servier Germany will start to co-promote Novartis’ potential blockbuster Entresto® (Sacubitril/Valsartan) used in cardiovascular diseases in Germany from November 1st...
PCI Announces Further Investment in Fully Contained Xcelodose® 600S Technology Delivering Excellence in Clinical Services
PCI Pharma Services is excited to announce further market leading investment in fully contained Xcelodose® 600S technology at our center...
Phase 3 Study Of Subcutanous Daratumumab Initiated Using Halozyme’s ENHANZE Technology
Halozyme Therapeutics, Inc., a biotechnology company developing novel oncology and drug-delivery therapies, today announced that Janssen Biotech, Inc. has initiated...
Daiichi Sankyo Announces ENLIVEN Phase 3 Study of Pexidartinib Met Primary Endpoint in Tenosynovial Giant Cell Tumor
Daiichi Sankyo Company, Limited announced that the pivotal phase 3 placebo-controlled ENLIVEN (NCT02371369) study of pexidartinib met its primary endpoint...
Latest News
About Us
Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.